Ashley Croft
Psychiatric/Mental Health · Caldwell, IDNPI 1316311954
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), speaking fees and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AbbVie at 54.7% of the total. Among psychiatric/mental health clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 393 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Alkermes, Inc.$1K
- Merz North America, Inc.$596
- Supernus Pharmaceuticals, Inc.$453
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$433
- E.r. Squibb & Sons, L.L.C.$430
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$5,15040%
- Food & beverage$7,55659%
- Education$540%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 150 | $6,975 |
| Alkermes, Inc. | 36 | $1,055 |
| Merz North America, Inc. | 7 | $596 |
| Supernus Pharmaceuticals, Inc. | 27 | $453 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $433 |
| E.r. Squibb & Sons, L.L.C. | 10 | $430 |
| Neuronetics, Inc. | 6 | $377 |
| Ironshore Pharmaceuticals Inc. | 21 | $338 |
| Corium, LLC | 24 | $325 |
| Vanda Pharmaceuticals Inc. | 17 | $318 |
| Otsuka America Pharmaceutical, Inc. | 12 | $238 |
| Eisai Inc. | 11 | $217 |
| Teva Pharmaceuticals USA, Inc. | 12 | $155 |
| Biogen | 4 | $140 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Tris Pharma Inc | 6 | $104 |
| Lundbeck LLC | 4 | $85 |
| Johnson & Johnson | 3 | $80 |
| Sunovion Pharmaceuticals Inc. | 4 | $75 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Pfizer | 3 | $68 |
| Merck | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$411
- VIVITROL$349
- COBENFY$289
- NEUROSTAR TMS THERAPY$152
- Dayvigo$104
How this compares
$12,760 in reported general payments places this provider in the 95th percentile of 221 psychiatric/mental health providers in Idaho.
Other psychiatric/mental health in Caldwell
- Adrian AvilaCaldwell$5K
- Blake McDonaldCaldwell$2K
- Jason MartinIdaho Falls$78K
- Misti NewsonBoise$56K
- Jared PetrickCoeur D Alene$32K
- Carey CrillBoise$19K
- Deborah RushMeridian$13K
- Scott WatkinsNampa$11K
- Julie SchraderBoise$9K
- Susan DayBoise$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.